MitoQ treatment of claudication: myofiber and micro-vessel pathology
MitoQ 治疗跛行:肌纤维和微血管病理学
基本信息
- 批准号:10608773
- 负责人:
- 金额:$ 63.11万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-30 至 2027-05-31
- 项目状态:未结题
- 来源:
- 关键词:AffectAgeAge-YearsAgreementAldehydesAntioxidantsArteriesBrain Hypoxia-IschemiaCilostazolClinicClinicalClinical ResearchCross-Over StudiesDNADevelopmentDiseaseDoseDrug TargetingElderlyElectron TransportElectronsEndotheliumExerciseFDA approvedFibrosisFunctional disorderGaitHemeHistopathologyHydrogen PeroxideHydroquinonesHydroxyl RadicalHypoxiaImpairmentIndividualInflammationInner mitochondrial membraneIschemiaLegLipid PeroxidationLipidsLong-Term EffectsLower ExtremityLungMeasurementMitochondriaMolecularMuscleMuscle MitochondriaMyalgiaMyopathyNADH dehydrogenase (ubiquinone)Older PopulationOralOxidative PhosphorylationOxidesOxygenPain in lower limbParticipantPathologicPathologyPatient CarePatientsPentoxifyllinePerformancePeripheral arterial diseasePharmaceutical PreparationsPhysical activityPhysiologicalPhysiologyPlacebo ControlPlacebosPlasmaProductionPropertyProteinsProtocols documentationQuality of lifeQuinonesRNARandomizedReactive Oxygen SpeciesRegimenRestSuccinate dehydrogenase (ubiquinone)Superoxide DismutaseSuperoxidesSystemTestingTherapeuticTimeUnsaturated FatsVasomotorVisitWalkingWomanWorkadductbaseclaudicationhemodynamicsimprovedmetabolic profilemitochondrial membraneoxidationoxidative damagepain reliefresponseuptake
项目摘要
Abstract
Claudication, the most common clinical presentation of patients with Peripheral Artery Disease (PAD), is a
severe functional limitation of the lower extremities identified as walking-induced leg muscle pain relieved by
rest. Numerous studies have identified a lower-leg myopathy in these patients. There is general agreement
that the proximate cause of this myopathy is dysfunctional mitochondria which produce oxidative damage in
response to repeated episodes of walking-induced ischemia/hypoxia. These patients have few therapeutic
options including only two FDA approved medications, Pentoxifylline and Cilostazol, which are modestly
effective. A promising medication for treatment of claudicating PAD patients is MitoQ an antioxidant that
concentrates several hundred-fold in mitochondria. The significant contribution of mitochondrial oxidative
damage to a wide range of pathologic conditions has stimulated clinical studies which have found MitoQ to be
safe and effective. Our group has documented improved walking performance of claudicating PAD patients
receiving a single dose of MitoQ. We propose to study, for the first time, the effects of long-term MitoQ
treatment on the myopathy and functional performance of claudicating PAD patients. Our Hypothesis:
Treatment of claudicating PAD patients with MitoQ for six months improves 1) patient performance determined
as walking performance, daily physical activity, and quality of life, 2) calf muscle histopathology and
pathophysiology, and 3) the systemic physiological parameters pulmonary O2 uptake (VO2) and metabolic
profile. These changes correlate directly with reduced oxidative damage to calf muscle mitochondria, improved
mitophagy, and improved mitochondrial function. We will test this hypothesis by implementing the following
Specific Aims. Specific Aim ‘1’ will test the hypothesis that a six-month regimen of MitoQ improves
performance determined as walking performance, daily physical activity, and quality of life of claudicating PAD
patients, in association with improved calf muscle histopathology & pathophysiology, and improved VO2 &
systemic metabolic profile. Specific Aim ‘2’ will test the hypothesis that a six-month regimen of MitoQ reduces
mitochondrial oxidative damage, improves mitophagy, and improves mitochondrial function of the voluminous,
myofiber-mitochondrial compartment and that these improvements correlate with improved performance of
claudicating PAD patients, improved calf muscle histopathology & pathophysiology, and improved VO2 &
systemic metabolic profile. Specific Aim ‘3’ will test the hypothesis that a six-month regimen of MitoQ
improves endothelial function and lower extremity hemodynamics, calf muscle heme oxygenation, and
endothelium-dependent vasomotor function of micro-vessels isolated from the affected calf muscle of
claudicating PAD patients, in association with improved mitochondrial function of the micro-vessels.
If our hypothesis is correct, the work will support a causal connection between mitochondrial oxidative
damage and PAD myopathy and patient performance; and identify MitoQ as a promising treatment for PAD.
抽象的
跛行是外周动脉疾病 (PAD) 患者最常见的临床表现,
下肢严重功能受限,被认为是行走引起的腿部肌肉疼痛,可通过以下方法缓解
休息。大量研究已发现这些患者患有小腿肌病。有普遍共识
这种肌病的直接原因是功能失调的线粒体,它会产生氧化损伤
对步行引起的缺血/缺氧反复发作的反应。这些患者的治疗方法很少
选项仅包括两种 FDA 批准的药物,己酮可可碱和西洛他唑,这两种药物的价格适中
有效的。 MitoQ 是一种治疗跛行 PAD 患者的有前途的药物,它是一种抗氧化剂,
线粒体中浓度数百倍。线粒体氧化的重要贡献
对多种病理状况的损害刺激了临床研究,这些研究发现 MitoQ
安全有效。我们的团队记录了跛行 PAD 患者步行能力的改善
接受单剂量 MitoQ。我们建议首次研究长期 MitoQ 的影响
对跛行 PAD 患者肌病和功能表现的治疗。我们的假设:
使用 MitoQ 治疗跛行 PAD 患者六个月可改善 1) 确定患者的表现
如步行表现、日常身体活动和生活质量,2) 小腿肌肉组织病理学和
病理生理学,3) 全身生理参数肺吸氧量 (VO2) 和代谢
轮廓。这些变化与小腿肌肉线粒体氧化损伤的减少、改善
线粒体自噬,改善线粒体功能。我们将通过实施以下内容来检验这个假设
具体目标。具体目标“1”将检验为期六个月的 MitoQ 方案改善的假设
表现确定为步行表现、日常体力活动和跛行 PAD 的生活质量
患者,与改善小腿肌肉组织病理学和病理生理学以及改善 VO2 和
全身代谢概况。具体目标“2”将检验以下假设:为期六个月的 MitoQ 方案可减少
线粒体氧化损伤,改善线粒体自噬,改善线粒体功能,
肌纤维线粒体室,这些改进与改善的性能相关
跛行 PAD 患者,改善小腿肌肉组织病理学和病理生理学,并改善 VO2 和
全身代谢概况。具体目标“3”将检验为期六个月的 MitoQ 方案的假设
改善内皮功能和下肢血流动力学、小腿肌肉血红素氧合,以及
从受影响的小腿肌肉中分离出的微血管的内皮依赖性血管舒缩功能
跛行的 PAD 患者,与微血管线粒体功能的改善有关。
如果我们的假设是正确的,这项工作将支持线粒体氧化之间的因果关系
损伤和 PAD 肌病以及患者表现;并确定 MitoQ 是一种有前景的 PAD 治疗方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
George Pasco Casale其他文献
George Pasco Casale的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('George Pasco Casale', 18)}}的其他基金
MitoQ treatment of claudication: myofiber and micro-vessel pathology
MitoQ 治疗跛行:肌纤维和微血管病理学
- 批准号:
10708069 - 财政年份:2022
- 资助金额:
$ 63.11万 - 项目类别:
Ramipril treatment of claudication: oxidative damage and muscle fibrosis
雷米普利治疗跛行:氧化损伤和肌肉纤维化
- 批准号:
9118839 - 财政年份:2015
- 资助金额:
$ 63.11万 - 项目类别:
MOLECULAR DOSIMETRY OF PAH AND ESTROGEN ADDUCTS IN URINE
尿液中多环芳烃和雌激素加合物的分子剂量测定
- 批准号:
6344726 - 财政年份:1999
- 资助金额:
$ 63.11万 - 项目类别:
MOLECULAR DOSIMETRY OF PAH AND ESTROGEN ADDUCTS IN URINE
尿液中多环芳烃和雌激素加合物的分子剂量测定
- 批准号:
6102529 - 财政年份:1999
- 资助金额:
$ 63.11万 - 项目类别:
MOLECULAR DOSIMETRY OF PAH AND ESTROGEN ADDUCTS IN URINE
尿液中多环芳烃和雌激素加合物的分子剂量测定
- 批准号:
6269401 - 财政年份:1998
- 资助金额:
$ 63.11万 - 项目类别:
MOLECULAR DOSIMETRY OF PAH AND ESTROGEN ADDUCTS IN URINE
尿液中多环芳烃和雌激素加合物的分子剂量测定
- 批准号:
6237045 - 财政年份:1997
- 资助金额:
$ 63.11万 - 项目类别:
MOLECULAR DOSIMETRY OF PAH AND ESTROGEN ADDUCTS IN URINE
尿液中多环芳烃和雌激素加合物的分子剂量测定
- 批准号:
5207556 - 财政年份:
- 资助金额:
$ 63.11万 - 项目类别:
相似国自然基金
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
- 批准号:JCZRQN202500010
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
- 批准号:2025JJ70209
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
- 批准号:2023JJ50274
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
- 批准号:n/a
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
- 批准号:81973577
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
- 批准号:81602908
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
- 批准号:81501928
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341426 - 财政年份:2024
- 资助金额:
$ 63.11万 - 项目类别:
Continuing Grant
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341424 - 财政年份:2024
- 资助金额:
$ 63.11万 - 项目类别:
Continuing Grant
PROTEMO: Emotional Dynamics Of Protective Policies In An Age Of Insecurity
PROTEMO:不安全时代保护政策的情绪动态
- 批准号:
10108433 - 财政年份:2024
- 资助金额:
$ 63.11万 - 项目类别:
EU-Funded
The role of dietary and blood proteins in the prevention and development of major age-related diseases
膳食和血液蛋白在预防和发展主要与年龄相关的疾病中的作用
- 批准号:
MR/X032809/1 - 财政年份:2024
- 资助金额:
$ 63.11万 - 项目类别:
Fellowship
Atomic Anxiety in the New Nuclear Age: How Can Arms Control and Disarmament Reduce the Risk of Nuclear War?
新核时代的原子焦虑:军控与裁军如何降低核战争风险?
- 批准号:
MR/X034690/1 - 财政年份:2024
- 资助金额:
$ 63.11万 - 项目类别:
Fellowship
Walkability and health-related quality of life in Age-Friendly Cities (AFCs) across Japan and the Asia-Pacific
日本和亚太地区老年友好城市 (AFC) 的步行适宜性和与健康相关的生活质量
- 批准号:
24K13490 - 财政年份:2024
- 资助金额:
$ 63.11万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Discovering the (R)Evolution of EurAsian Steppe Metallurgy: Social and environmental impact of the Bronze Age steppes metal-driven economy
发现欧亚草原冶金的(R)演变:青铜时代草原金属驱动型经济的社会和环境影响
- 批准号:
EP/Z00022X/1 - 财政年份:2024
- 资助金额:
$ 63.11万 - 项目类别:
Research Grant
ICF: Neutrophils and cellular senescence: A vicious circle promoting age-related disease.
ICF:中性粒细胞和细胞衰老:促进与年龄相关疾病的恶性循环。
- 批准号:
MR/Y003365/1 - 财政年份:2024
- 资助金额:
$ 63.11万 - 项目类别:
Research Grant
Doctoral Dissertation Research: Effects of age of acquisition in emerging sign languages
博士论文研究:新兴手语习得年龄的影响
- 批准号:
2335955 - 财政年份:2024
- 资助金额:
$ 63.11万 - 项目类别:
Standard Grant
Shaping Competition in the Digital Age (SCiDA) - Principles, tools and institutions of digital regulation in the UK, Germany and the EU
塑造数字时代的竞争 (SCiDA) - 英国、德国和欧盟的数字监管原则、工具和机构
- 批准号:
AH/Y007549/1 - 财政年份:2024
- 资助金额:
$ 63.11万 - 项目类别:
Research Grant